Macrophage Migration-inhibitory Factor Levels in Serum of Patients with Ovarian Cancer Correlates with Poor Prognosis

Macrophage migration-inhibitory factor (MIF) levels in serum of patients (n=68) correlate inversely with disease-free survival (DFS) after completed adjuvant or first-line therapy of ovarian cancer. The bold blue line indicates the regression line, the green lines indicate the 5-95% confidence interval.

Patients with disease-free survival of more than 9 months (n=31) had a significantly lower MIF serum level at the time of diagnosis (mean 1.1784 ng/ml) in comparison to patients with lower DFS (n=34, mean 2.254 ng/ml). This is in line with the findings for the high-MIF and low-MIF groups of patients. The box boundaries limit the interval of 25% to 75% of all data, the middle line indicates the mean of all data. The bars above and below the box indicate the 5% and 95% interval.

Patients of the low-Macrophage migration-inhibitory factor (MIF) group (n=31) had longer duration of overall survival (OS, mean 39.8 months) in comparison to patients of the high-MIF group (n=37, mean 20.9 months). The box boundaries limit the interval of 25% to 75% of all data, the middle line indicates the mean of all data. The bars above and below the box indicate the 5% and 95% interval.